Elan reports positive MS drug trials
DUBLIN (Reuters) – Elan Corporation Plc said on Friday the
latest trials of its multiple sclerosis drug Tysabri on
sufferers showed significant positive effects on their quality
“The Tysabri study data show not only significant
reductions in relapses and disability, but also suggest
improved quality of life. This is very encouraging,” the
company said in a statement.
Elan and drugmaker Biogen Idec faced a fresh delay in
getting Tysabri back to the market last month after U.S.
regulators extended their review of the drug by three months
until June 28.
Tysabri was pulled abruptly last year following a link with
a life-threatening side effect, but an independent advisory
panel recommended that multiple sclerosis sufferers be allowed
to take the drug, subject to certain risk controls.
Elan said the results of its Phase III trials of the drug
were presented this week at the annual meeting of the American
Academy of Neurology in San Diego.
It said it was the first time it had observed positive
findings on so-called “quality of life measures” in a Phase III
Elan said patients treated with the drug had a reduction in
the risk of visual decline and a reduction in the risk of the
rate of disability.
Multiple sclerosis causes progressive disability that can
include blurred vision, weakness, poor muscle coordination and
loss of memory and mental function as nerves lose their
(Additional reporting by Pete Harrison in London)